Is BioNTech Stock a No-Brainer Buy on the Dip?
The company is coming back into the spotlight thanks to recent developments.
BioNTech (BNTX) has underperformed the market this year, with its shares rising merely 6% compared to the S&P 500's 12% gain. Over the past five years, BioNTech has lost 70% of its value. The biotech company developed the vaccine Comirnaty in collaboration with Pfizer (PFE), which was highly popular in the early stages of the pandemic.
At its peak, Comirnaty generated nearly $38 billion in sales, contributing to BioNTech's solid financial performance. However, as the pandemic subsided, demand for the vaccine waned, and some governments made it more difficult for individuals to receive vaccinations. Consequently, Comirnaty's sales have been lackluster in recent years, leading many to question whether BioNTech is poised for a resurgence or if it is more likely to continue its decline over the next few years.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.